Biogen sued for alleged PBM kickbacks scheme to boost Tecfidera in wake of generics
Fierce Pharma
AUGUST 21, 2024
As Biogen’s relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive ki | A multi-employer health benefit plan in Illinois accused the drugmaker of scheming with pharmacy benefit managers to keep its Tecfidera in a more favorable spot on their formularies.
Let's personalize your content